Last reviewed · How we verify

Doravirine (DOR)

Walter K. Kraft · FDA-approved active Small molecule

Doravirine (DOR) is a Non-nucleoside reverse transcriptase inhibitor (NNRTI) Small molecule drug developed by Walter K. Kraft. It is currently FDA-approved for HIV-1 infection in treatment-naïve and treatment-experienced adults (in combination antiretroviral therapy). Also known as: Pifeltro, MK-1439.

Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV reverse transcriptase to prevent viral replication.

Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV reverse transcriptase to prevent viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults (in combination antiretroviral therapy).

At a glance

Generic nameDoravirine (DOR)
Also known asPifeltro, MK-1439
SponsorWalter K. Kraft
Drug classNon-nucleoside reverse transcriptase inhibitor (NNRTI)
TargetHIV-1 reverse transcriptase
ModalitySmall molecule
Therapeutic areaInfectious Disease / Virology
PhaseFDA-approved

Mechanism of action

Doravirine binds to the non-nucleoside binding pocket of HIV-1 reverse transcriptase, inhibiting the enzyme's ability to convert viral RNA into DNA. This prevents the integration of viral genetic material into the host cell genome and stops HIV replication. It is structurally distinct from earlier NNRTIs and has activity against some drug-resistant HIV strains.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Doravirine (DOR)

What is Doravirine (DOR)?

Doravirine (DOR) is a Non-nucleoside reverse transcriptase inhibitor (NNRTI) drug developed by Walter K. Kraft, indicated for HIV-1 infection in treatment-naïve and treatment-experienced adults (in combination antiretroviral therapy).

How does Doravirine (DOR) work?

Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV reverse transcriptase to prevent viral replication.

What is Doravirine (DOR) used for?

Doravirine (DOR) is indicated for HIV-1 infection in treatment-naïve and treatment-experienced adults (in combination antiretroviral therapy).

Who makes Doravirine (DOR)?

Doravirine (DOR) is developed and marketed by Walter K. Kraft (see full Walter K. Kraft pipeline at /company/walter-k-kraft).

Is Doravirine (DOR) also known as anything else?

Doravirine (DOR) is also known as Pifeltro, MK-1439.

What drug class is Doravirine (DOR) in?

Doravirine (DOR) belongs to the Non-nucleoside reverse transcriptase inhibitor (NNRTI) class. See all Non-nucleoside reverse transcriptase inhibitor (NNRTI) drugs at /class/non-nucleoside-reverse-transcriptase-inhibitor-nnrti.

What development phase is Doravirine (DOR) in?

Doravirine (DOR) is FDA-approved (marketed).

What are the side effects of Doravirine (DOR)?

Common side effects of Doravirine (DOR) include Headache, Nausea, Diarrhea, Fatigue, Rash.

What does Doravirine (DOR) target?

Doravirine (DOR) targets HIV-1 reverse transcriptase and is a Non-nucleoside reverse transcriptase inhibitor (NNRTI).

Related